Search Results

• • 2,617 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Pristiq

  From:Physician Assistants' Prescribing Reference (Vol. 15, Issue 2)

  Summer 2008164 words Brief article, Drug ... 1070LCompany: Wyeth Rx Pharmacologic class: Antidepressant (SNRI) Active ingredient: Desvenlafaxine (as succinate) 50mg, 100mg; ext-rel tabs. Indication: Major depressive disorder (MDD). Pharmacology:...

• Brintellix

  From:Nurse Practitioners' Prescribing Reference (Vol. 21, Issue 1) Peer-Reviewed

  Spring 2014162 words Brief article, Drug ... 1340L Companies: Takeda and Lundbeck | Rx Pharmacologic class: Serotonergic antidepressant. Active ingredient: Vortioxetine 5mg, 10mg, 20 mg; tablets. Indication: Treatment of adults with...

• Pristiq

  From:Nurse Practitioners' Prescribing Reference (Vol. 15, Issue 2) Peer-Reviewed

  Summer 2008165 words Brief article, Drug ... 1070LCompany: Wyeth Rx Pharmacologic class: Antidepressant (SNRI) Active ingredient: Desvenlafaxine (as succinate) 50mg, 100mg; ext-rel tabs. Indication: Major depressive disorder (MDD). Pharmacology:...

• Systematic review of neurocognition and occupational functioning in major depressive disorder

  Authors:Vanessa C Evans, Sarah SL Chan, Grant L Iverson, David J Bond, Lakshmi N Yatham, and Raymond W LamFrom:Neuropsychiatry (Vol. 3, Issue 1) Peer-Reviewed

  Feb. 20135,122 words Article 1460LAuthor(s): Vanessa C Evans 1 , Sarah SL Chan 1 , Grant L Iverson 1 , David J Bond 1 , Lakshmi N Yatham 1 , Raymond W Lam [*] 2 Practice points * Major depressive disorder is a burdensome illness that disrupts...

• Measurement of prevalence of 'major depressive syndrome' among Indian patients attending pain clinic with chronic pain using PHQ-9 scale

  Authors:Debjyoti Dutta, Saswata Bharati, Chinmoy Roy, and Gautam DasFrom:Journal of Anaesthesiology Clinical Pharmacology (Vol. 29, Issue 1) Peer-Reviewed

  January-March 20134,161 words Report 1800LByline: Debjyoti. Dutta, Saswata. Bharati, Chinmoy. Roy, Gautam. Das Background: Presence of major depressive syndrome (MDS) in chronic pain patients (CPPs) requires more attention from the clinicians because of its...

• An investigation of the three factor model of personality and its relationships with clinical characteristics in major mood disorders/Major duygudurum bozukluklarinda kisiligin uc boyutlu degerlendirilmesi ve klinik ozelliklerle iliskisi

  Authors:Okan Ekinci and Asli EkinciFrom:Archives of Neuropsychiatry (Vol. 50, Issue 1) Peer-Reviewed

  Mar. 20135,142 words Report 1410LABSTRACT Background: Personality make individuals prone to particular affective states and therefore, it may have a role in the etiology of mood disorders. Although Eysenck Personality Questionnaire is. one of the...

• Enhanced care by community health workers in improving treatment adherence to antidepressant medication in rural women with major depression

  Authors:Johnson Pradeep, Anton Isaacs, Deepthi Shanbag, Sumithra Selvan, and Krishnamachari SrinivasanFrom:Indian Journal of Medical Research (Vol. 139, Issue 2) Peer-Reviewed

  Feb. 20144,861 words Report 1460LByline: Johnson. Pradeep, Anton. Isaacs, Deepthi. Shanbag, Sumithra. Selvan, Krishnamachari. Srinivasan Background & objectives: Depression remains largely undiagnosed in women residing in rural India and...

• Relationship of asymmetrical dimethylarginine, nitric oxide, and sustained attention during attack in patients with major depressive disorder

  Authors:Serpil Canpolat, Ismet Kirpinar, Erdem Deveci, Hulya Aksoy, Zafer Bayraktutan, Ibrahim Eren, et al.From:The Scientific World Journal (Vol. 14) Peer-Reviewed

  Annual 20143,952 words Report 1210LWe investigated the relationship of serum nitric oxide (NO) and asymmetrical dimethylarginine (ADMA) levels with cognitive functioning in patients with major depressive disorder (MDD). 41MDD patients (Beck depression...

• Factors related to suicide attempts among individuals with major depressive disorder

  Authors:Chidchanok Ruengorn, Kittipong Sanichwankul, Wirat Niwatananun, Suwat Mahatnirunkul, Wanida Pumpaisalchai, and Jayanton PatumanondFrom:International Journal of General Medicine (Vol. 5) Peer-Reviewed

  Annual 20123,768 words Report 1520LMajor depressive disorder (MDD) is the leading cause of suicidal behaviors. Risk related to suicide attempts among individuals with MDD remains uninvestigated in upper northern Thailand, where the completed suicide rate...

• Treatment of major depressive disorder

  Authors:Neil S. Skolnik and Curtis OlsonFrom:Family Practice News (Vol. 41, Issue 17)

  Oct. 15, 2011960 words Disease/Disorder ove... 1170LThe American Psychiatric Association's guidelines on treatment of major depression emphasize a well-coordinated approach. They call for physicians to establish a therapeutic relationship; evaluate functional...

• Current and emerging somatic treatment strategies in psychotic major depression

  Authors:Pinhas N Dannon, Katherine Lowengrub, Yehudit Gonopolski, and Moshe KotlerFrom:Expert Review of Neurotherapeutics (Vol. 6, Issue 1) Peer-Reviewed

  Jan. 20065,775 words Report Author(s): Pinhas N Dannon [[dagger]] 1 , Katherine Lowengrub 2 , Yehudit Gonopolski 3 , Moshe Kotler end4 Keywords: electroconvulsive therapy; deep- brain stimulation; major depressive disorder; mood stabilizers;...

• Studies from Center for Addiction and Mental Health Yield New Information about Pharmacogenomics (Genetic variation in IL-1?, IL-2, IL-6, TSPO and BDNF and response to duloxetine or placebo treatment in major depressive disorder)

  From:Obesity, Fitness & Wellness Week

  Apr. 2, 2016312 words Brief article, Repor... 1360L2016 APR 2 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on Biotechnology are presented in a new report. According to news reporting from Toronto, Canada, by NewsRx...

• Is placebo useful in the treatment of major depression in clinical practice?

  Authors:Carlo Marchesi, Chiara De Panfilis, Matteo Tonna, and Paolo OssolaFrom:Neuropsychiatric Disease and Treatment (Vol. 9) Peer-Reviewed

  Annual 20134,301 words Clinical report 2230LBackground: For many years, placebo has been defined by its inert content and use in clinical trials. In recent years, several studies have demonstrated its effect in the treatment of major depression. The aim of this...

• Levomilnacipran SR effective for major depressive disorder

  From:The Brown University Psychopharmacology Update (Vol. 24, Issue 7)

  July 2013312 words Brief article, Clini... 1540LIn a phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and tolerability of fixed-dose levomilnacipran sustained release (SR) compared with placebo in patients with major depressive...

• Dense Cranial Electroacupuncture Stimulation for Major Depressive Disorder-A Single-Blind, Randomized, Controlled Study

  Authors:Zhang-Jin Zhang, Roger Ng, Sui Cheung Man, Tsui Yin Jade Li, Wendy Wong, Qing-Rong Tan, et al.From:PLoS ONE (Vol. 7, Issue 1) Peer-Reviewed

  Jan. 6, 20125,086 words Clinical report 1540LAuthor(s): Zhang-Jin Zhang 1 , * , Roger Ng 1 , Sui Cheung Man 1 , Tsui Yin Jade Li 1 , Wendy Wong 1 , Qing-Rong Tan 3 , Hei Kiu Wong 1 , Ka-Fai Chung 4 , Man-Tak Wong 2 , Wai-Kiu Alfert Tsang 2 , Ka-chee Yip 2 , Eric...

• Tractography of the Brainstem in Major Depressive Disorder Using Diffusion Tensor Imaging

  Authors:Yun Ju C. Song, Mayuresh S. Korgaonkar, Lucy V. Armstrong, Sarah Eagles, Leanne M. Williams, and Stuart M. GrieveFrom:PLoS ONE (Vol. 9, Issue 1) Peer-Reviewed

  Jan. 21, 20144,511 words Article 1490LAuthor(s): Yun Ju C. Song 1,2, Mayuresh S. Korgaonkar 1,2, Lucy V. Armstrong 1, Sarah Eagles 1, Leanne M. Williams 1,2,3, Stuart M. Grieve 1,* Introduction Major depressive disorder (MDD) is the fourth most...

• Daily activity level improvement with antidepressant medications predicts long-term clinical outcomes in outpatients with major depressive disorder

  Authors:Manish K. Jha, Raymond B. Teer, Abu Minhajuddin, Tracy L. Greer, and A. John RushFrom:Neuropsychiatric Disease and Treatment (Vol. 13) Peer-Reviewed

  Annual 20176,092 words Report 1830LBackground: Major depressive disorder (MDD) significantly impacts performance of both work- and nonwork-related routine daily activities. We have shown that work productivity is significantly impaired in employed MDD...

• Cost-utility of collaborative care for the treatment of comorbid major depressive disorder in outpatients with chronic physical conditions. A randomized controlled trial in the general hospital setting (CC-DIM)

  Authors:Maartje Goorden, Christina M. van der Feltz-Cornelis, Kirsten M. van Steenbergen-Weijenburg, Eva K. Horn, Aartjan T.F. Beekman, and Leona Hakkaart-van RoijenFrom:Neuropsychiatric Disease and Treatment (Vol. 13) Peer-Reviewed

  Annual 20176,824 words Report 1640LPurpose: Major depressive disorder (MDD) is highly prevalent in patients with a chronic physical condition, and this comorbidity has a negative influence on quality of life, health care costs, self-care, morbidity, and...

• Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response

  Authors:Sanjay J., Dennis S. Charney, Dan V. Iosifescu, and Katherine E. BurdickFrom:Psychopharmacology (Vol. 231, Issue 3) Peer-Reviewed

  Feb. 1, 20145,353 words Report 1450LRationale The N-methyl-D-aspartate (NMDA) glutamate receptor antagonist ketamine has demonstrated rapid antidepressant effects in patients with treatment-resistant depression (TRD). Despite the promise of a novel and...

• TPH1A218C polymorphism and temperament in major depression

  Authors:Kadri Andre, Olli Kampman, Merja Viikki, Ari Illi, Eija Setala-Soikkeli, Outi Poutanen, et al.From:BMC Psychiatry (Vol. 13, Issue 1) Peer-Reviewed

  Apr. 18, 20133,150 words Report 1390LAuthor(s): Kadri Andre1,2 , Olli Kampman2,5 , Merja Viikki2,6 , Ari Illi2,7 , Eija Setälä-Soikkeli4 , Outi Poutanen2,3 , Nina Mononen8 , Esa Leinonen2,3 and Terho Lehtimäki2,8 Background Tryptophan hydroxylase...